Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDF Cardiff Oncology, Inc.

Post-Mkt 04-16 16:10:53 EDT

1.69

-0.01

-0.59%

盘后1.69

+0.000.00%

16:10 EDT

High1.73	Low1.65	Vol667.00K
Open1.69	D1 Closing1.70	Amplitude4.71%
Mkt Cap115.54M	Tradable Cap111.08M	Total Shares68.36M
T/O1.13M	T/O Rate1.01%	Tradable Shares65.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":1.69,"timestamp":1776369600000,"preClose":1.7,"halted":0,"volume":666998,"hourTrading":{"tag":"盘后","latestPrice":1.69,"preClose":1.69,"latestTime":"16:10 EDT","volume":347,"amount":586.43,"timestamp":1776370204355,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005882352941176476,"floatShares":65730400,"shares":68364979,"eps":-0.686345,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"04-16 16:10:53 EDT","open":1.69,"high":1.73,"low":1.65,"amount":1125306.999756,"amplitude":0.047059,"askPrice":1.74,"askSize":88,"bidPrice":1.62,"bidSize":593,"shortable":3,"etf":0,"ttmEps":-0.686345,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776384000000},"marketStatusCode":4,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":1.7,"preClose":1.7,"latestTime":"09:27 EDT","volume":255,"amount":433.79643749999997,"timestamp":1776346070002,"change":0,"changeRate":0,"amplitude":0.005882},"postHourTrading":{"tag":"盘后","latestPrice":1.69,"preClose":1.69,"latestTime":"16:10 EDT","volume":347,"amount":586.43,"timestamp":1776370204355,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.726832,"impliedVol":0.1806,"impliedVolPercentile":0.028},"requestUrl":"/m/hq/s/CRDF/wiki","defaultTab":"wiki","newsList":[{"id":"2626153024","title":"BRIEF-Cardiff Oncology Announces Key Leadership Appointments To Strengthen Executive Team For Next Phase Of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2626153024","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626153024?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:01","pubTimestamp":1775772108,"startTime":"0","endTime":"0","summary":"BRIEF-Cardiff Oncology Announces Key Leadership Appointments To Strengthen Executive Team For Next Phase Of GrowthApril 9 (Reuters) - Cardiff Oncology Inc CRDF.O:CARDIFF ONCOLOGY ANNOUNCES KEY LEADERS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA3NHRTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130851","title":"Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130851","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130851?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764897,"startTime":"0","endTime":"0","summary":"Cardiff Oncology named board member Mani Mohindru as president and CEO, following her stint as interim CEO.Josh Muntner was appointed CFO effective April 6; he previously served as CFO of Imvax and Mesoblast.Ajay Aggarwal was named COO effective April 27; he most recently served as SVP and head of clinical development at Aclaris Therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6mHz76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","CRDF","BK7501","IE00BN0W2T93.GBP","BK4585","MSB.AU","LU2210149790.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","BK4007","IE00BN0W2W23.USD","BK7067","LU2095319765.USD","BK7508","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626137020","title":"Cardiff Oncology Inc - Appoints Josh Muntner as CFO Effective April 6 and Ajay Aggarwal as COO Effective April 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2626137020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626137020?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA3NHRTC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626078137","title":"Cardiff Oncology Inc - Appoints Mani Mohindru as President and CEO; to Continue as Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2626078137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626078137?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA3NHRTC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624825706","title":"Cardiff Oncology CEO Mark Erlander resigns as director after stepping down as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2624825706","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624825706?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:18","pubTimestamp":1775161097,"startTime":"0","endTime":"0","summary":"Cardiff Oncology entered separation agreements dated March 27, 2026 with former CEO Mark Erlander and former CFO James Levine.Agreements follow their departures disclosed Jan. 26, 2026, tied to a strategic review.Erlander also signed a consulting agreement with Cardiff Oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8RZN5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387604","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387604?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:04","pubTimestamp":1774717440,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLYX","RXT","BK4161","SLS","BK4023","EVCM","LCID","BK4182","BK4606","CD","BK4144","SERV","ATLN","NNE","BK4608","NFE","HURA","BK4139","BK4212","BK4008","CV","BK4138","BK4077","BK4603","CRDF","NNEX","BK4082","BYND","BK4116","BK4548","BK4604","PDYN","GETY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826019","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826019?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:05","pubTimestamp":1774613100,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","HURA","NNEX","CV","BK4023","RXT","EVCM","BK4138","BK4548","BK4139","NNE","BK4144","ATLN","BK4116","BK4082","BK4077","LCID","NFE","CRDF","BK4161","BYND","BK4603","SERV","CD","BK4008","BK4606","BK4212","PDYN","GETY","BK4182","BK4604","FLYX","BK4608"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622770860","title":"Noble Financial Sticks to Its Buy Rating for Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622770860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622770860?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:25","pubTimestamp":1774545912,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cardiff Oncology, with a price target of $12.00. LeBoyer...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-its-buy-rating-for-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-its-buy-rating-for-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBL","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622377448","title":"Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), CSPC Pharmaceutical Group (CHJTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622377448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622377448?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:30","pubTimestamp":1774513804,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiff Oncology (CRDF) and CSPC Pharmaceutical Grou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-cardiff-oncology-crdf-cspc-pharmaceutical-group-chjtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-cardiff-oncology-crdf-cspc-pharmaceutical-group-chjtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSX","BLSG","LU0029874061.USD","BK4581","LABU","XBI","BK4588","BK4139","CHJTF","LU0128526141.USD","BK4137","BK4112","BK4585","BK4007","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620806537","title":"Cardiff Oncology to host KOL webinar on first-line RAS-mutated metastatic colorectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620806537","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620806537?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:01","pubTimestamp":1774004482,"startTime":"0","endTime":"0","summary":"Cardiff Oncology will host a key opinion leader webinar on March 25, 2026 at 4:30 p.m. ET focused on first-line RAS-mutated metastatic colorectal cancer.The discussion is scheduled to include Scott Kopetz and Heinz-Josef Lenz, along with interim CEO Mani Mohindru.The release includes an Events link for registration and webcast access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8XlRsS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620640244","title":"Cardiff Oncology to present onvansertib and T-DXd preclinical data at AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620640244","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620640244?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:05","pubTimestamp":1773918306,"startTime":"0","endTime":"0","summary":"Cardiff Oncology plans to present preclinical data at the AACR Annual Meeting 2026 on April 19, 2026, from 2:00 PM to 5:00 PM PT in San Diego.The presentation is a poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan  and reverses its resistance in therapy-resistant HER2-low breast cancer models” .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbMHkyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","BK4588","IE00B64PRP62.GBP","CRDF","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614625075","title":"Cardiff Oncology to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2614625075","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614625075?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:02","pubTimestamp":1772139775,"startTime":"0","endTime":"0","summary":"Cardiff Oncology to Participate in Three Upcoming Investor Conferences               Cardiff Oncology Inc. said its management will participate in three investor conferences in March 2026: the TD Cowe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL6d9fDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","NDAQ","BK4139","SG9999014013.SGD","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","SG9999014039.USD","BK4112","BK4585","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","CRDF","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614054211","title":"Cardiff Oncology Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614054211","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614054211?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:01","pubTimestamp":1772056876,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc reports results for the quarter ended December 31 - Earnings SummaryCardiff Oncology Inc CRDF.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter ended Dec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL8N3ZL2ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614035449","title":"Cardiff Oncology Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035449","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614035449?lang=en_us&edition=fundamental","pubTime":"2026-02-25 22:50","pubTimestamp":1772031000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRDF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 09:50 ET (14:50 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614779291","title":"Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF) and Alphatec Holdings (ATEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614779291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614779291?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:50","pubTimestamp":1771991409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiff Oncology (CRDF – Research Report) and Alphat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cardiff-oncology-crdf-and-alphatec-holdings-atec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cardiff-oncology-crdf-and-alphatec-holdings-atec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDF","LU0128526141.USD","ATEC","BK4137","BK4588","HCSG","BK4082","LU0029874061.USD","XBI","LU0566484027.USD","XLV","BK4139","BK4585","LABU","BK4581","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614572345","title":"Press Release: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614572345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614572345?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:30","pubTimestamp":1771968600,"startTime":"0","endTime":"0","summary":"Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:. Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026. Continued Dr. Mohindru, \"Based on these results, we plan to advance the 30 mg dose of onvansertib with FOLFIRI/bev into our proposed registrational program and expect to provide detailed data and registrational plans after discussions with the FDA in the first half of 2026. As we transition into late-stage clinical development and continue to strengthen our leadership and operational teams, we remain focused on disciplined execution, progressing our lead program toward a potential new standard of care in first-line RAS-mutated mCRC.\". randomized Phase 2 trial evaluating onvansertib in combination with","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613758179","title":"Cardiff Oncology Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758179","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758179?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884008,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc  expected to post a loss of19cents a share - Earnings Preview Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to  show a fall in quarterly revenue when it reports  results on Febr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ2DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612044104","title":"Cardiff Oncology to Present at Oppenheimer Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612044104","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612044104?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502434,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4n9Qy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","BK4585","BK4139","BK4588","LU2210150020.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610665477","title":"Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Brigitte Lindsay","url":"https://stock-news.laohu8.com/highlight/detail?id=2610665477","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610665477?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:00","pubTimestamp":1770670840,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Brigitte Ute Lindsay as the beneficial owner, serving in the role of Chief Accounting Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4DPqQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Brigitte Lindsay","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607749872","title":"Cardiff Oncology Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2607749872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607749872?lang=en_us&edition=fundamental","pubTime":"2026-01-29 01:27","pubTimestamp":1769621220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRDF/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 12:27 ET (17:27 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.0897},{"period":"1month","weight":-0.1053},{"period":"3month","weight":-0.3907},{"period":"6month","weight":-0.2237},{"period":"1year","weight":-0.4218},{"period":"ytd","weight":-0.395}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.5,"avgChangeRate":0.28397},{"month":3,"riseRate":0.357143,"avgChangeRate":0.075052},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.06345},{"month":5,"riseRate":0.461538,"avgChangeRate":0.052242},{"month":6,"riseRate":0.384615,"avgChangeRate":0.287657},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.07931},{"month":8,"riseRate":0.571429,"avgChangeRate":0.100833},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction